PDB Short entry for 2XWT HEADER SIGNALING PROTEIN/IMMUNE SYSTEM 05-NOV-10 2XWT TITLE CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A BLOCKING TYPE TITLE 2 TSHR AUTOANTIBODY COMPND MOL_ID: 1; COMPND 2 MOLECULE: THYROID BLOCKING HUMAN AUTOANTIBODY K1-70 HEAVY CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: FAB FRAGMENT HEAVY CHAIN, RESIDUES 1-229; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: THYROID BLOCKING HUMAN AUTOANTIBODY K1-70 LIGHT CHAIN; COMPND 8 CHAIN: B; COMPND 9 FRAGMENT: FAB FRAGMENT LIGHT CHAIN, RESIDUES 1-213; COMPND 10 ENGINEERED: YES; COMPND 11 MOL_ID: 3; COMPND 12 MOLECULE: THYROTROPIN RECEPTOR; COMPND 13 CHAIN: C; COMPND 14 FRAGMENT: LEUCINE RICH REPEAT DOMAIN, RESIDUES 22-260; COMPND 15 SYNONYM: THYROID-STIMULATING HORMONE RECEPTOR, TSH-R; COMPND 16 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: MOUSE-HUMAN HETEROHYBRIDOMA CELL LINE; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 37965; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: MOUSE-HUMAN HETEROHYBRIDOMA CELL LINE; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 37965; SOURCE 13 MOL_ID: 3; SOURCE 14 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 15 ORGANISM_COMMON: HUMAN; SOURCE 16 ORGANISM_TAXID: 9606; SOURCE 17 EXPRESSION_SYSTEM: TRICHOPLUSIA NI; SOURCE 18 EXPRESSION_SYSTEM_TAXID: 7111; SOURCE 19 EXPRESSION_SYSTEM_CELL_LINE: HIGH FIVE; SOURCE 20 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS SIGNALING PROTEIN-IMMUNE SYSTEM COMPLEX, GPCR, GRAVES' DISEASE, KEYWDS 2 AUTOIMMUNITY, RECEPTOR-AUTOANTIBODY COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.SANDERS,P.SANDERS,S.YOUNG,K.KABELIS,S.BAKER,A.SULLIVAN,M.EVANS, AUTHOR 2 J.CLARK,J.WILMOT,X.HU,E.ROBERTS,M.POWELL,R.NUNEZ MIGUEL,J.FURMANIAK, AUTHOR 3 B.REES SMITH REVDAT 4 29-JUL-20 2XWT 1 COMPND REMARK HETNAM LINK REVDAT 4 2 1 SITE ATOM REVDAT 3 03-APR-19 2XWT 1 SOURCE REVDAT 2 28-JUN-17 2XWT 1 REMARK REVDAT 1 09-MAR-11 2XWT 0 JRNL AUTH P.SANDERS,S.YOUNG,J.SANDERS,K.KABELIS,S.BAKER,A.SULLIVAN, JRNL AUTH 2 M.EVANS,J.CLARK,J.WILMOT,X.HU,E.ROBERTS,M.POWELL, JRNL AUTH 3 R.NUNEZ MIGUEL,J.FURMANIAK,B.REES SMITH JRNL TITL CRYSTAL STRUCTURE OF THE TSH RECEPTOR (TSHR) BOUND TO A JRNL TITL 2 BLOCKING-TYPE TSHR AUTOANTIBODY. JRNL REF J.MOL.ENDOCRINOL. V. 46 81 2011 JRNL REFN ISSN 0952-5041 JRNL PMID 21247981 JRNL DOI 10.1530/JME-10-0127 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.SANDERS,D.Y.CHIRGADZE,P.SANDERS,S.BAKER,A.SULLIVAN, REMARK 1 AUTH 2 A.BHARDWAJA,J.BOLTON,M.REEVE,N.NAKATAKE,M.EVANS,T.RICHARDS, REMARK 1 AUTH 3 M.POWELL,R.N.MIGUEL,T.L.BLUNDELL,J.FURMANIAK,B.R.SMITH REMARK 1 TITL CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A REMARK 1 TITL 2 THYROID-STIMULATING AUTOANTIBODY REMARK 1 REF THYROID V. 17 395 2007 REMARK 1 REFN ISSN 1050-7256 REMARK 1 PMID 17542669 REMARK 1 DOI 10.1089/THY.2007.0034 REMARK 1 REFERENCE 2 REMARK 1 AUTH M.EVANS,J.SANDERS,T.TAGAMI,P.SANDERS,S.YOUNG,E.ROBERTS, REMARK 1 AUTH 2 J.WILMOT,X.HU,K.KABELIS,J.CLARK,S.HOLL,T.RICHARDS,A.COLLYER, REMARK 1 AUTH 3 J.FURMANIAK,B.R.SMITH REMARK 1 TITL MONOCLONAL AUTOANTIBODIES TO THE TSH RECEPTOR, ONE WITH REMARK 1 TITL 2 STIMULATING ACTIVITY AND ONE WITH BLOCKING ACTIVITY, REMARK 1 TITL 3 OBTAINED FROM THE SAME BLOOD SAMPLE. REMARK 1 REF CLINICAL ENDOCRINOL. V. 73 404 2010 REMARK 1 REFN ISSN 0300-0664 REMARK 1 PMID 20550534 REMARK 1 DOI 10.1111/J.1365-2265.2010.03831.X REMARK 1 REFERENCE 3 REMARK 1 AUTH B.REES SMITH,J.SANDERS,M.EVANS,T.TAGAMI,J.FURMANIAK REMARK 1 TITL TSH RECEPTOR - AUTOANTIBODY INTERACTIONS. REMARK 1 REF HORM.METAB.RES. V. 41 448 2009 REMARK 1 REFN ISSN 0018-5043 REMARK 1 PMID 19530271 REMARK 1 REFERENCE 4 REMARK 1 AUTH J.SANDERS,M.EVANS,L.D.K.E.PREMAWARDHANA,H.DEPRAETERE, REMARK 1 AUTH 2 J.JEFFREYS,T.RICHARDS,J.FURMANIAK,B.R.SMITH REMARK 1 TITL HUMAN MONOCLONAL THYROID STIMULATING AUTOANTIBODY REMARK 1 REF LANCET V. 362 126 2003 REMARK 1 REFN ISSN 0140-6736 REMARK 1 PMID 12867115 REMARK 1 REFERENCE 5 REMARK 1 AUTH J.SANDERS,J.JEFFREYS,H.DEPRAETERE,M.EVANS,T.RICHARDS, REMARK 1 AUTH 2 A.KIDDIE,K.BRERETON,L.D.K.E.PREMAWARDHANA,D.Y.CHIRGADZE, REMARK 1 AUTH 3 R.N.MIGUEL,T.L.BLUNDELL,J.FURMANIAK,B.R.SMITH REMARK 1 TITL CHARACTERISTICS OF A HUMAN MONOCLONAL AUTOANTIBODY TO THE REMARK 1 TITL 2 THYROTROPIN RECEPTOR: SEQUENCE STRUCTURE AND FUNCTION REMARK 1 REF THYROID V. 14 560 2004 REMARK 1 REFN ISSN 1050-7256 REMARK 1 PMID 15320966 REMARK 1 DOI 10.1089/1050725041692918 REMARK 1 REFERENCE 6 REMARK 1 AUTH R.NUNEZ MIGUEL,J.SANDERS,D.Y.CHIRGADZE,J.FURMANIAK, REMARK 1 AUTH 2 B.REES SMITH REMARK 1 TITL THYROID STIMULATING AUTOANTIBODY M22 MIMICS TSH BINDING TO REMARK 1 TITL 2 THE TSH RECEPTOR LEUCINE RICH DOMAIN: A COMPARATIVE REMARK 1 TITL 3 STRUCTURAL STUDY OF PROTEIN-PROTEIN INTERACTIONS. REMARK 1 REF J.MOL.ENDOCRINOL. V. 42 381 2009 REMARK 1 REFN ISSN 0952-5041 REMARK 1 PMID 19221175 REMARK 1 DOI 10.1677/JME-08-0152 REMARK 1 REFERENCE 7 REMARK 1 AUTH J.SANDERS,J.BOLTON,P.SANDERS,J.JEFFREYS,N.NAKATAKE, REMARK 1 AUTH 2 T.RICHARDS,M.EVANS,A.KIDDIE,S.SUMMERHAYES,E.ROBERTS, REMARK 1 AUTH 3 R.N.MIGUEL,J.FURMANIAK,B.R.SMITH REMARK 1 TITL EFFECTS OF TSH RECEPTOR MUTATIONS ON BINDING AND BIOLOGICAL REMARK 1 TITL 2 ACTIVITY OF MONOCLONAL ANTIBODIES AND TSH REMARK 1 REF THYROID V. 16 1195 2006 REMARK 1 REFN ISSN 1050-7256 REMARK 1 PMID 17199429 REMARK 1 DOI 10.1089/THY.2006.16.1195 REMARK 1 REFERENCE 8 REMARK 1 AUTH J.SANDERS,R.N.MIGUEL,J.BOLTON,A.BHARDWAJA,P.SANDERS, REMARK 1 AUTH 2 N.NAKATAKE,M.EVANS,J.FURMANIAK,B.R.SMITH REMARK 1 TITL MOLECULAR INTERACTIONS BETWEEN THE TSH RECEPTOR AND A REMARK 1 TITL 2 THYROID-STIMULATING MONOCLONAL AUTOANTIBODY REMARK 1 REF THYROID V. 17 699 2007 REMARK 1 REFN ISSN 1050-7256 REMARK 1 PMID 17725428 REMARK 1 DOI 10.1089/THY.2007.0041 REMARK 1 REFERENCE 9 REMARK 1 AUTH R.N.MIGUEL,J.SANDERS,D.Y.CHIRGADZE,T.L.BLUNDELL,J.FURMANIAK, REMARK 1 AUTH 2 B.REES SMITH REMARK 1 TITL FSH AND TSH BINDING TO THEIR RESPECTIVE RECEPTORS: REMARK 1 TITL 2 SIMILARITIES, DIFFERENCES AND IMPLICATION FOR GLYCOPROTEIN REMARK 1 TITL 3 HORMONE SPECIFICITY REMARK 1 REF J.MOL.ENDOCRINOL. V. 41 145 2008 REMARK 1 REFN ISSN 0952-5041 REMARK 1 PMID 18606720 REMARK 1 DOI 10.1677/JME-08-0040 REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0072 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 66.98 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 94.2 REMARK 3 NUMBER OF REFLECTIONS : 53657 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.179 REMARK 3 R VALUE (WORKING SET) : 0.177 REMARK 3 FREE R VALUE : 0.227 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 2861 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.90 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.95 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2692 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 64.80 REMARK 3 BIN R VALUE (WORKING SET) : 0.2620 REMARK 3 BIN FREE R VALUE SET COUNT : 138 REMARK 3 BIN FREE R VALUE : 0.3140 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 5028 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 106 REMARK 3 SOLVENT ATOMS : 798 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 0.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 16.89 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.32000 REMARK 3 B22 (A**2) : -0.70000 REMARK 3 B33 (A**2) : -0.62000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.156 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.149 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.087 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 2.911 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.952 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.924 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 5303 ; 0.011 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 3469 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 7261 ; 1.344 ; 1.985 REMARK 3 BOND ANGLES OTHERS (DEGREES): 8529 ; 0.845 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 666 ; 6.478 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 197 ;37.409 ;24.822 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 814 ;12.288 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 14 ;18.945 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 852 ; 0.080 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 5804 ; 0.006 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 983 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 3315 ; 0.686 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 1328 ; 0.166 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 5393 ; 1.259 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1988 ; 1.965 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1864 ; 3.211 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. U VALUES REFINED INDIVIDUALLY. REMARK 4 REMARK 4 2XWT COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 05-NOV-10. REMARK 100 THE DEPOSITION ID IS D_1290045740. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-NOV-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 HF REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : COLLIMATOR REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 56573 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.5 REMARK 200 DATA REDUNDANCY : 5.100 REMARK 200 R MERGE (I) : 0.09000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 11.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 64.8 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.30000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 3G04 REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.62 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 16% PEG 3350, 0.2 M SODIUM MALONATE PH REMARK 280 5., PH 5.0 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 41.51000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 50.63500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 44.65000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 50.63500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 41.51000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 44.65000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 6450 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 35920 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.3 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 128 REMARK 465 LYS A 129 REMARK 465 SER A 130 REMARK 465 THR A 131 REMARK 465 SER A 132 REMARK 465 GLY A 133 REMARK 465 GLN B 1 REMARK 465 MET C 22 REMARK 465 GLY C 23 REMARK 465 TRP C 258 REMARK 465 THR C 259 REMARK 465 LEU C 260 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 43 CE NZ REMARK 470 LYS A 213 CD CE NZ REMARK 470 LYS A 228 CG CD CE NZ REMARK 470 SER A 229 OG REMARK 470 LYS B 156 CE NZ REMARK 470 LYS B 163 CD CE NZ REMARK 470 LYS B 166 CD CE NZ REMARK 470 THR B 212 OG1 CG2 REMARK 470 GLU B 213 CG CD OE1 OE2 REMARK 470 ARG C 65 CG CD NE CZ NH1 NH2 REMARK 470 LYS C 250 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH B 453 O HOH C 461 1.90 REMARK 500 O HOH C 407 O HOH C 492 1.92 REMARK 500 O HOH C 461 O HOH C 584 2.11 REMARK 500 O HOH B 453 O HOH C 584 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 GLU A 1 CD GLU A 1 OE1 0.083 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR A 27 111.26 -164.37 REMARK 500 ALA A 88 166.71 179.80 REMARK 500 ASP B 27B -95.91 -105.95 REMARK 500 ASN B 51 -46.51 76.29 REMARK 500 ILE C 85 83.17 66.10 REMARK 500 GLU C 124 70.13 58.38 REMARK 500 GLU C 178 -146.78 -118.31 REMARK 500 LEU C 184 66.97 -119.43 REMARK 500 ASP C 203 -87.13 -100.49 REMARK 500 ALA C 254 46.80 -143.02 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A 605 DISTANCE = 5.94 ANGSTROMS REMARK 525 HOH A 606 DISTANCE = 6.09 ANGSTROMS REMARK 525 HOH A 607 DISTANCE = 6.30 ANGSTROMS REMARK 525 HOH A 608 DISTANCE = 6.37 ANGSTROMS REMARK 525 HOH A 609 DISTANCE = 6.39 ANGSTROMS REMARK 525 HOH A 610 DISTANCE = 6.74 ANGSTROMS REMARK 525 HOH C 627 DISTANCE = 5.95 ANGSTROMS REMARK 525 HOH C 628 DISTANCE = 6.31 ANGSTROMS REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1XUM RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE LIGAND-BINDING REGION OF AGLYCOPROTEIN REMARK 900 HORMONE RECEPTOR REMARK 900 RELATED ID: 3G04 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A THYROID- REMARK 900 STIMULATING AUTOANTIBODY DBREF 2XWT A 1 229 PDB 2XWT 2XWT 1 229 DBREF 2XWT B 1 213 PDB 2XWT 2XWT 1 213 DBREF 2XWT C 22 260 UNP P16473 TSHR_HUMAN 22 260 SEQRES 1 A 221 GLU VAL GLN LEU VAL GLN SER GLY ALA GLU VAL LYS LYS SEQRES 2 A 221 PRO GLY GLN SER LEU LYS ILE SER CYS LYS ALA SER GLY SEQRES 3 A 221 TYR SER LEU THR ASP ASN TRP ILE GLY TRP VAL ARG GLN SEQRES 4 A 221 LYS PRO GLY LYS GLY LEU GLU TRP MET GLY ILE ILE TYR SEQRES 5 A 221 PRO GLY ASP SER ASP THR ARG TYR SER PRO SER PHE GLN SEQRES 6 A 221 GLY GLN VAL THR ILE SER ALA ASP LYS SER ILE ASN THR SEQRES 7 A 221 ALA TYR LEU GLN TRP SER SER LEU LYS ALA SER ASP THR SEQRES 8 A 221 ALA ILE TYR TYR CYS VAL GLY LEU ASP TRP ASN TYR ASN SEQRES 9 A 221 PRO LEU ARG TYR TRP GLY PRO GLY THR LEU VAL THR VAL SEQRES 10 A 221 SER SER ALA SER THR LYS GLY PRO SER VAL PHE PRO LEU SEQRES 11 A 221 ALA PRO SER SER LYS SER THR SER GLY GLY THR ALA ALA SEQRES 12 A 221 LEU GLY CYS LEU VAL LYS ASP TYR PHE PRO GLU PRO VAL SEQRES 13 A 221 THR VAL SER TRP ASN SER GLY ALA LEU THR SER GLY VAL SEQRES 14 A 221 HIS THR PHE PRO ALA VAL LEU GLN SER SER GLY LEU TYR SEQRES 15 A 221 SER LEU SER SER VAL VAL THR VAL PRO SER SER SER LEU SEQRES 16 A 221 GLY THR GLN THR TYR ILE CYS ASN VAL ASN HIS LYS PRO SEQRES 17 A 221 SER ASN THR LYS VAL ASP LYS LYS VAL GLU PRO LYS SER SEQRES 1 B 214 GLN SER VAL LEU THR GLN PRO PRO SER VAL SER ALA ALA SEQRES 2 B 214 PRO GLY GLN LYS VAL THR ILE SER CYS SER GLY SER SER SEQRES 3 B 214 SER ASP ILE GLY SER ASN TYR VAL SER TRP TYR GLN GLN SEQRES 4 B 214 PHE PRO GLY THR ALA PRO LYS LEU LEU ILE TYR ASP ASN SEQRES 5 B 214 ASN LYS ARG PRO SER ALA ILE PRO ASP ARG PHE SER GLY SEQRES 6 B 214 SER LYS SER GLY THR SER ALA THR LEU GLY ILE THR GLY SEQRES 7 B 214 LEU GLN THR GLY ASP GLU ALA ASP TYR TYR CYS GLY THR SEQRES 8 B 214 TRP ASP SER ARG LEU GLY ILE ALA VAL PHE GLY GLY GLY SEQRES 9 B 214 THR GLN LEU THR VAL LEU GLY GLN PRO LYS ALA ALA PRO SEQRES 10 B 214 SER VAL THR LEU PHE PRO PRO SER SER GLU GLU LEU GLN SEQRES 11 B 214 ALA ASN LYS ALA THR LEU VAL CYS LEU VAL SER ASP PHE SEQRES 12 B 214 TYR PRO GLY ALA VAL THR VAL ALA TRP LYS ALA ASP GLY SEQRES 13 B 214 SER PRO VAL LYS VAL GLY VAL GLU THR THR LYS PRO SER SEQRES 14 B 214 LYS GLN SER ASN ASN LYS TYR ALA ALA SER SER TYR LEU SEQRES 15 B 214 SER LEU THR PRO GLU GLN TRP LYS SER HIS ARG SER TYR SEQRES 16 B 214 SER CYS ARG VAL THR HIS GLU GLY SER THR VAL GLU LYS SEQRES 17 B 214 THR VAL ALA PRO THR GLU SEQRES 1 C 239 MET GLY CYS SER SER PRO PRO CYS GLU CYS HIS GLN GLU SEQRES 2 C 239 GLU ASP PHE ARG VAL THR CYS LYS ASP ILE GLN ARG ILE SEQRES 3 C 239 PRO SER LEU PRO PRO SER THR GLN THR LEU LYS LEU ILE SEQRES 4 C 239 GLU THR HIS LEU ARG THR ILE PRO SER HIS ALA PHE SER SEQRES 5 C 239 ASN LEU PRO ASN ILE SER ARG ILE TYR VAL SER ILE ASP SEQRES 6 C 239 VAL THR LEU GLN GLN LEU GLU SER HIS SER PHE TYR ASN SEQRES 7 C 239 LEU SER LYS VAL THR HIS ILE GLU ILE ARG ASN THR ARG SEQRES 8 C 239 ASN LEU THR TYR ILE ASP PRO ASP ALA LEU LYS GLU LEU SEQRES 9 C 239 PRO LEU LEU LYS PHE LEU GLY ILE PHE ASN THR GLY LEU SEQRES 10 C 239 LYS MET PHE PRO ASP LEU THR LYS VAL TYR SER THR ASP SEQRES 11 C 239 ILE PHE PHE ILE LEU GLU ILE THR ASP ASN PRO TYR MET SEQRES 12 C 239 THR SER ILE PRO VAL ASN ALA PHE GLN GLY LEU CYS ASN SEQRES 13 C 239 GLU THR LEU THR LEU LYS LEU TYR ASN ASN GLY PHE THR SEQRES 14 C 239 SER VAL GLN GLY TYR ALA PHE ASN GLY THR LYS LEU ASP SEQRES 15 C 239 ALA VAL TYR LEU ASN LYS ASN LYS TYR LEU THR VAL ILE SEQRES 16 C 239 ASP LYS ASP ALA PHE GLY GLY VAL TYR SER GLY PRO SER SEQRES 17 C 239 LEU LEU ASP VAL SER GLN THR SER VAL THR ALA LEU PRO SEQRES 18 C 239 SER LYS GLY LEU GLU HIS LEU LYS GLU LEU ILE ALA ARG SEQRES 19 C 239 ASN THR TRP THR LEU MODRES 2XWT ASN C 77 ASN GLYCOSYLATION SITE MODRES 2XWT ASN C 99 ASN GLYCOSYLATION SITE MODRES 2XWT ASN C 177 ASN GLYCOSYLATION SITE MODRES 2XWT ASN C 198 ASN GLYCOSYLATION SITE HET NAG D 1 14 HET NAG D 2 14 HET NAG E 1 14 HET NAG E 2 14 HET BMA E 3 11 HET MAN E 4 11 HET NAG C 303 14 HET NAG C 304 14 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM BMA BETA-D-MANNOPYRANOSE HETNAM MAN ALPHA-D-MANNOPYRANOSE FORMUL 4 NAG 6(C8 H15 N O6) FORMUL 5 BMA C6 H12 O6 FORMUL 5 MAN C6 H12 O6 FORMUL 8 HOH *798(H2 O) HELIX 1 AA1 LYS A 73 ILE A 75 5 3 HELIX 2 AA2 LYS A 83 THR A 87 5 5 HELIX 3 AA3 SER A 163 ALA A 165 5 3 HELIX 4 AA4 SER A 196 LEU A 198 5 3 HELIX 5 AA5 LYS A 213 ASN A 216 5 4 HELIX 6 AA6 GLN B 79 GLU B 83 5 5 HELIX 7 AA7 SER B 121 ALA B 127 1 7 HELIX 8 AA8 THR B 182 HIS B 189 1 8 SHEET 1 AA1 4 GLN A 3 GLN A 6 0 SHEET 2 AA1 4 LEU A 18 SER A 25 -1 O LYS A 23 N VAL A 5 SHEET 3 AA1 4 THR A 77 TRP A 82 -1 O LEU A 80 N ILE A 20 SHEET 4 AA1 4 THR A 68 ASP A 72 -1 N SER A 70 O TYR A 79 SHEET 1 AA2 6 GLU A 10 LYS A 12 0 SHEET 2 AA2 6 THR A 107 VAL A 111 1 O THR A 110 N GLU A 10 SHEET 3 AA2 6 ALA A 88 LEU A 95 -1 N ALA A 88 O VAL A 109 SHEET 4 AA2 6 TRP A 33 GLN A 39 -1 N VAL A 37 O TYR A 91 SHEET 5 AA2 6 GLU A 46 ILE A 51 -1 O MET A 48 N TRP A 36 SHEET 6 AA2 6 THR A 57 TYR A 59 -1 O ARG A 58 N ILE A 50 SHEET 1 AA3 4 GLU A 10 LYS A 12 0 SHEET 2 AA3 4 THR A 107 VAL A 111 1 O THR A 110 N GLU A 10 SHEET 3 AA3 4 ALA A 88 LEU A 95 -1 N ALA A 88 O VAL A 109 SHEET 4 AA3 4 TYR A 102 TRP A 103 -1 O TYR A 102 N GLY A 94 SHEET 1 AA4 4 SER A 120 LEU A 124 0 SHEET 2 AA4 4 THR A 137 TYR A 147 -1 O LYS A 145 N SER A 120 SHEET 3 AA4 4 TYR A 185 PRO A 194 -1 O LEU A 187 N VAL A 144 SHEET 4 AA4 4 VAL A 171 THR A 173 -1 N HIS A 172 O VAL A 190 SHEET 1 AA5 4 SER A 120 LEU A 124 0 SHEET 2 AA5 4 THR A 137 TYR A 147 -1 O LYS A 145 N SER A 120 SHEET 3 AA5 4 TYR A 185 PRO A 194 -1 O LEU A 187 N VAL A 144 SHEET 4 AA5 4 VAL A 177 LEU A 178 -1 N VAL A 177 O SER A 186 SHEET 1 AA6 3 THR A 153 TRP A 157 0 SHEET 2 AA6 3 ILE A 207 HIS A 212 -1 O ASN A 209 N SER A 156 SHEET 3 AA6 3 THR A 217 LYS A 222 -1 O VAL A 219 N VAL A 210 SHEET 1 AA7 5 SER B 9 ALA B 13 0 SHEET 2 AA7 5 THR B 102 VAL B 106 1 O THR B 105 N VAL B 11 SHEET 3 AA7 5 ALA B 84 ASP B 92 -1 N TYR B 86 O THR B 102 SHEET 4 AA7 5 SER B 34 GLN B 38 -1 N SER B 34 O GLY B 89 SHEET 5 AA7 5 LYS B 45 ILE B 48 -1 O LEU B 47 N TRP B 35 SHEET 1 AA8 4 SER B 9 ALA B 13 0 SHEET 2 AA8 4 THR B 102 VAL B 106 1 O THR B 105 N VAL B 11 SHEET 3 AA8 4 ALA B 84 ASP B 92 -1 N TYR B 86 O THR B 102 SHEET 4 AA8 4 ILE B 95B PHE B 98 -1 O VAL B 97 N THR B 90 SHEET 1 AA9 3 VAL B 19 SER B 24 0 SHEET 2 AA9 3 SER B 70 ILE B 75 -1 O LEU B 73 N ILE B 21 SHEET 3 AA9 3 PHE B 62 SER B 67 -1 N SER B 63 O GLY B 74 SHEET 1 AB1 4 SER B 114 PHE B 118 0 SHEET 2 AB1 4 ALA B 130 PHE B 139 -1 O LEU B 135 N THR B 116 SHEET 3 AB1 4 TYR B 173 LEU B 181 -1 O SER B 177 N CYS B 134 SHEET 4 AB1 4 VAL B 159 THR B 161 -1 N GLU B 160 O TYR B 178 SHEET 1 AB2 4 SER B 114 PHE B 118 0 SHEET 2 AB2 4 ALA B 130 PHE B 139 -1 O LEU B 135 N THR B 116 SHEET 3 AB2 4 TYR B 173 LEU B 181 -1 O SER B 177 N CYS B 134 SHEET 4 AB2 4 SER B 165 LYS B 166 -1 N SER B 165 O ALA B 174 SHEET 1 AB3 4 SER B 153 VAL B 155 0 SHEET 2 AB3 4 THR B 145 ALA B 150 -1 N ALA B 150 O SER B 153 SHEET 3 AB3 4 TYR B 192 HIS B 198 -1 O ARG B 195 N ALA B 147 SHEET 4 AB3 4 SER B 203 VAL B 209 -1 O VAL B 205 N VAL B 196 SHEET 1 AB411 CYS C 31 GLN C 33 0 SHEET 2 AB411 ARG C 38 CYS C 41 -1 O THR C 40 N HIS C 32 SHEET 3 AB411 THR C 56 ILE C 60 1 O LYS C 58 N CYS C 41 SHEET 4 AB411 ARG C 80 SER C 84 1 O TYR C 82 N LEU C 59 SHEET 5 AB411 HIS C 105 THR C 111 1 O ARG C 109 N VAL C 83 SHEET 6 AB411 PHE C 130 THR C 136 1 O PHE C 134 N ILE C 108 SHEET 7 AB411 PHE C 153 THR C 159 1 O GLU C 157 N LEU C 131 SHEET 8 AB411 THR C 179 LYS C 183 1 O LYS C 183 N LEU C 156 SHEET 9 AB411 LYS C 201 TYR C 206 1 O TYR C 206 N LEU C 182 SHEET 10 AB411 LEU C 230 ASP C 232 1 O ASP C 232 N VAL C 205 SHEET 11 AB411 GLU C 251 ILE C 253 1 O ILE C 253 N LEU C 231 SHEET 1 AB5 3 THR C 66 ILE C 67 0 SHEET 2 AB5 3 GLN C 91 LEU C 92 1 O GLN C 91 N ILE C 67 SHEET 3 AB5 3 TYR C 116 ILE C 117 1 O TYR C 116 N LEU C 92 SHEET 1 AB6 2 PHE C 97 TYR C 98 0 SHEET 2 AB6 2 LEU C 122 LYS C 123 1 O LYS C 123 N PHE C 97 SHEET 1 AB7 3 SER C 166 ILE C 167 0 SHEET 2 AB7 3 SER C 191 VAL C 192 1 O SER C 191 N ILE C 167 SHEET 3 AB7 3 VAL C 215 ILE C 216 1 O VAL C 215 N VAL C 192 SSBOND 1 CYS A 22 CYS A 92 1555 1555 2.06 SSBOND 2 CYS A 142 CYS A 208 1555 1555 2.03 SSBOND 3 CYS B 23 CYS B 88 1555 1555 2.08 SSBOND 4 CYS B 134 CYS B 194 1555 1555 2.04 SSBOND 5 CYS C 24 CYS C 29 1555 1555 2.05 SSBOND 6 CYS C 31 CYS C 41 1555 1555 2.08 LINK ND2 ASN C 77 C1 NAG D 1 1555 1555 1.44 LINK ND2 ASN C 99 C1 NAG C 304 1555 1555 1.46 LINK ND2 ASN C 177 C1 NAG C 303 1555 1555 1.44 LINK ND2 ASN C 198 C1 NAG E 1 1555 1555 1.44 LINK O4 NAG D 1 C1 NAG D 2 1555 1555 1.45 LINK O4 NAG E 1 C1 NAG E 2 1555 1555 1.44 LINK O4 NAG E 2 C1 BMA E 3 1555 1555 1.45 LINK O6 BMA E 3 C1 MAN E 4 1555 1555 1.45 CISPEP 1 PHE A 148 PRO A 149 0 -6.46 CISPEP 2 GLU A 150 PRO A 151 0 -0.82 CISPEP 3 TYR B 140 PRO B 141 0 0.17 CISPEP 4 PRO C 27 PRO C 28 0 -1.96 CISPEP 5 GLY C 227 PRO C 228 0 0.68 CRYST1 83.020 89.300 101.270 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012045 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011198 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009875 0.00000